Sign in
WithdrawnNo phase

A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

Key facts

Who runs it
Boehringer Ingelheim
Where
Germany, Netherlands, Spain, and Sweden6 sites in 4 countriesChoose a country to see its sites
Trial code
Status
Withdrawn
Started
24 Nov 2022
Ended
1 Oct 2024
Type of study
Observational
Treatments tested
  • Dabigatran Etexilate (DE)
Record updated
26 June 2024
Why it stopped
No patients were screened in the study.

Who can take part

Age
Up to 2 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Written informed consent from parents/care givers
  • Children from birth to less than 2 years of age
  • Initiation of Dabigatran Etexilate (DE) administration:; for treatment of Venous thromboembolism (VTE) or/and; prevention of recurrent VTE due to presence of unresolved clinical VTE risk factor(s)

Who cannot take part

  • Participation in any Randomised Clinical Trial or use of any investigational product
  • Any contraindications to DE according to the EU Summary of Product Characteristics (SmPC)

Where is this trial?

It has sites in 4 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study is designed to collect and evaluate Dabigatran Etexilate (DE) safety in the context of routine anticoagulation care provided in the European Union (EU)/European Economic Area (EEA) for children under 2 years of age.

Read full original descriptionShow less

The non-interventional study will be conducted in paediatric hospitals or paediatric departments of EEA member states where Venous thromboembolism (VTE) patients of the evaluated age group are treated.

The group in the trial

  • Pediatric patients eligible for Dabigatran Etexilate (DE) VTE treatment and secondary VTE prevention

    Treatment: Dabigatran Etexilate (DE)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety of Dabigatran Etexilate (DE) for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Paediatric Patients From Birth to Less Than 2 Years of Age: a Prospective European Non-interventional Cohort Study Based on New Data Collection
Record updated
26 June 2024